<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00521755</url>
  </required_header>
  <id_info>
    <org_study_id>SF-01</org_study_id>
    <nct_id>NCT00521755</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of Using Seraffix LTB - (Laser Tissue Bonding) System</brief_title>
  <official_title>Evaluation of Safety and Efficacy of Using Seraffix LTB - (Laser Tissue Bonding) System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seraffix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seraffix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of using Seraffix LTB&#xD;
      system for soft tissue bonding.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dermatologic wounds can be closed by a variety of methods. The choice of a particular closure&#xD;
      technique should be based on the patient, wound, tissue characteristics, and anatomic&#xD;
      location. The purpose of these closure methods is an approximation of wound lips until the&#xD;
      regenerate tissue reach a phase, where it is closed and can sustain the daily tensile forces.&#xD;
&#xD;
      Several methods are used for wounds closure such as sutures, staples, tapes, tissue adhesives&#xD;
      and laser energy. There have been two fundamental approaches to laser assisted bonding of&#xD;
      tissues:&#xD;
&#xD;
        1. Laser welding-heating the approximated edges of cuts in tissues by a laser beam;&#xD;
&#xD;
        2. Laser soldering- applying a biological solder onto the approximated edges and heating&#xD;
           the solder (and the underlying tissue).&#xD;
&#xD;
      Seraffix has developed the Seraffix LTB (Laser Tissue Bonding) System - a laser system for&#xD;
      soft tissue bonding. This innovative system includes features that make laser soldering&#xD;
      suitable for clinical use. The Seraffix system is composed of CO2 laser device, propriety&#xD;
      grip device (Clamps) and soldering agent (Human Albumin).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary study endpoint will be to establish the safety of using the Seraffix System for tissue bonding and wounds closure. Safety will be established by paucity of serious adverse events and adverse events.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Re-intervention: A subject is scored a success (1) if he had No Re-intervention by 3 months; otherwise he is scored a failure (0). 2. Wound dehiscence of at least 50% of wound length:</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Dehiscence, Surgical Wound</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Seraffix LTB</intervention_name>
    <description>laser soldering for soft tissue wounds</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male/Female age 18-60.&#xD;
&#xD;
          -  Subject is scheduled for laparoscopic cholecystectomy surgery.&#xD;
&#xD;
          -  Subject able to comprehend and give informed consent for participation in this study.&#xD;
&#xD;
          -  Signed informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable angina and/or congestive heart failure requiring hospitalization within the&#xD;
             last 6 months prior to screening.&#xD;
&#xD;
          -  Acute infection requiring intravenous antibiotics at the time of screening.&#xD;
&#xD;
          -  Bleeding, coagulation and or clotting disorders.&#xD;
&#xD;
          -  Diabetes mellitus: IDDM or NIDDM.&#xD;
&#xD;
          -  HIV positive or any other immunosuppressive disorder.&#xD;
&#xD;
          -  Renal failure (Serum creatinine &gt;2.0 mg/dl).&#xD;
&#xD;
          -  Inflammatory and or allergic diseases or condition of the skin: Psoriasis, Eczema or&#xD;
             dermatitis.&#xD;
&#xD;
          -  Any concomitant infection - viral or bacterial.&#xD;
&#xD;
          -  Drug abuse.&#xD;
&#xD;
          -  Use of steroids.&#xD;
&#xD;
          -  Infection / abscess / pain in treatment target area.&#xD;
&#xD;
          -  Pregnancy or lactating.&#xD;
&#xD;
          -  History of keloid scarring.&#xD;
&#xD;
          -  Use of aspirin or antioxidants&#xD;
&#xD;
          -  Subject is suffering extreme general weakness.&#xD;
&#xD;
          -  Subject objects to the study protocol.&#xD;
&#xD;
          -  Known cognitive or psychiatric disorder&#xD;
&#xD;
          -  Concurrent participation in any other clinical study.&#xD;
&#xD;
          -  Physician objection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ossama Hatoum, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>HaEmek Medical Center, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haemek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>August 26, 2007</study_first_submitted>
  <study_first_submitted_qc>August 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2007</study_first_posted>
  <last_update_submitted>June 8, 2011</last_update_submitted>
  <last_update_submitted_qc>June 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Hanna Levy, Clinical Study Consultant</name_title>
    <organization>Seraffix</organization>
  </responsible_party>
  <keyword>Laser bonding soft tissue albumin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound Dehiscence</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

